Drug Discovery · Portland, OR · Founded 2013 · Privately Held (backing)
Operator of a cardiometabolic therapeutics platform intended to address treatment-resistant diabetes and related metabolic conditions. Sparrow Pharmaceuticals is based in Portland, OR and was founded in 2013. It was valued at $139 million at its later-stage round in Sep 2025, the last priced event on record. It has raised $146 million across 4 recorded rounds; the latest was a $95 million Series B in Sep 2025.
PMV mark · valuation
$139.0M
Oct 2026
Priced at
its later-stage round
Sep 2025
Total raised
$145.8M
Last round
Later Stage VC (Series B)
Sep 2025
Cap table — not yet on record
Sparrow Pharmaceuticals's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Sparrow Pharmaceuticals with a free account
·The complete investor list: 11 names
·Watch Sparrow Pharmaceuticals: the Monday email on marks, rounds and moves
Where does Sparrow Pharmaceuticals's cap table come from?
Share classes are assembled from certificates of incorporation, priced-round filings, and disclosures across Sparrow Pharmaceuticals's 4 recorded funding rounds.
